Results of treating 53 hairy cell leukemia patients with alpha-interferon.
Fifty-three hairy cell leukemia patients were treated with low dose recombinant and natural alpha-interferon for 7 or 13 months with a marked improvement in peripheral blood and bone marrow findings. Our results suggest that daily injections have no advantage over three weekly injections, but longer treatment (12-13 months) is better than shorter treatment (6-7 months). The possibility of a relapse raises the issue of the place of splenectomy in the treatment strategy. Since the definition of remission and of relapse is based on the histological changes in the bone marrow, the necessity for the quantification of the hairy cell infiltration on bone marrow sections is stressed.
Flandrin
G
G
Laboratoire Central d'Hematologie, Hopital Saint-Louis, Paris, France.
Castaigne
S
S
Sigaux
F
F
Degos
L
L
D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D006410:Hematopoiesis; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000628:therapy*; D007958:Leukocyte Count; D010976:Platelet Count; D011994:Recombinant Proteins / Q000627:therapeutic use; D013156:Splenectomy; D013997:Time Factors
D007370:Interferon Type I; D011994:Recombinant Proteins